Share tips of the week
MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
Three to buy
GSK
(Investors Chronicle) GSK’s multi-faceted fight against Covid-19 – developing a vaccine, repurposing existing medicines, and supporting the UK’s diagnostics infrastructure – has “underscored the breadth of its operations and its dominance in multiple arenas”. Its pipeline is strong too, with 37 medicines and 15 vaccines in development, which should drive future growth. A forward price/earnings ratio of 13 seems “undemanding” considering its diversified revenues, research and development focus and generous dividend. 1,771p
Inspecs
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
(The Daily Telegraph) This Aim-listed company designs, makes and distributes eyewear frames for well-known opticians including Specsavers and Vision Express as well as other retailers such as Next and Walmart. Covid-19 has had some effect, but it “will not stop people needing to get their vision corrected” and the company’s vertically-integrated model will help margins recover quickly. Sales rose by 7% last year and underlying profits by 20%. It did not pay a dividend last year but there are hints of one in 2021. One for patient fans of smaller companies. 195p
Target Healthcare
(Shares) Despite the effects of coronavirus on the care home sector, the need for quality accommodation for older and more vulnerable people “has arguably never been greater”. This real-estate investment trust focuses on quality purpose-built care homes with single-occupancy rooms and ensuite facilities, and offers a yield of 6.2%. It is “particularly well-positioned” in a post-virus world where infection control is especially important. 107p
Three to sell
Aveva
(The Mail on Sunday) Covid-19 has forced companies to do more online than they ever expected. That’s excellent news for software group Aveva. Around 40% of sales come from software facilitating website design while the rest relates to making machinery more efficient; monitoring systems will alert supervisors if a piece of equipment is malfunctioning, for instance. The group has over 16,000 customers worldwide and joined the FTSE 100 last year. However, the global slowdown may now hamper growth and the shares have had “a good run” in recent years. Take some profits. 4,081p
JD Wetherspoon
(Motley Fool UK) This has been “a nightmare year” for the pub group. The lockdown forced it to furlough 99% of its workforce. Customers are now returning but “the environment is likely to remain challenging”. Social-distancing measures mean it has to discourage large groups and it won’t be showing football in July. Most Britons also remain nervous about dining out. Net debt is almost three times equity and founder Tim Martin recently sold £5m of shares. Avoid. 901p
Senior
(Investors Chronicle) Aerospace technology and components specialist Senior was in trouble before the virus as Boeing stopped producing its 737 Max plane. All airlines have since cut their orders, while the downturn in the car and lorry sector has hit Senior too: the flexonics division, which deals with vehicle emissions, recorded a 27% drop in sales in the first half. The group is axing another 12% of its workforce and could struggle for years. 59p
...and the rest
Investors Chronicle
More people working from home has boosted demand for software protection. Cybersecurity firm Avast is “good value for the market leader”. Buy (579p). Investors waiting to get into tabletop wargames-maker Games Workshop at a more reasonable price “might be disappointed”. Buy and hold for the long term (8,110p). The rising price of copper is good news for Atalaya Mining – buy (163p).
Shares
Defence specialist QinetiQ “continues to deliver on its growth strategy and remains a buy” (341p). Ocado has a “winning formula”, and as Britain’s first online supermarket, it enjoys first-mover advantage. “Keep buying” (1,187p). Second-hand car dealer Motorpoint suffered under lockdown, but business is picking up again. Buy (190p). The management behind Luceco, a maker of LED lighting and portable power products, “has done an exceptional job during the pandemic” and the future is bright. Buy (116p).
The Times
While Covid-19 and the West’s rift with China create medium-term risk, asset manager Ashmore should benefit from longer-term emerging-market growth. Hold (418p). “Resilient” credit checker Experian will profit from a move to a more digitised world. Buy (2,835p).
The Daily Telegraph
The Triple Point Social Housing Reit is an ethical play on property rents with the promise of a stable income. Hold (106p). Renewables fund Greencoat UK Wind has established a record of “attractive returns” and the shares are “worth tucking away” (144p).
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Rightmove: UK asking prices up more than usual but Budget uncertainty remains
News The property website’s latest House Price Index shows sales are rising and buyers are benefiting from more choice – but will the Budget dent market confidence?
By Marc Shoffman Published
-
8 of the best properties for sale with striking gardens
Properties with striking gardens – from a 17th-century longhouse in Carmarthen, Wales, to a 16th-century manor house in Hampshire with formal parterre gardens.
By Natasha Langan Published
-
Are shares disconnecting from reality?
What effect is passive investing having on shares, and are ETFs going the same way?
By Alex Rankine Published
-
The peak of the AI frenzy has passed
When did the AI frenzy peak and what does it mean for tech companies?
By Alex Rankine Published
-
The battle against heart disease and how to invest in it
Heart disease is soaring due to rising obesity and an ageing population. But new drugs, treatments and diagnostic tools are on the way.
By Dr Matthew Partridge Published
-
Woodside Energy: an undervalued energy play
Woodside Energy offers a cheap way to invest in the growth of the global LNG market. Should you invest?
By Rupert Hargreaves Published
-
Small caps: how to ride the recovery wave of UK equities
Professional investor Ken Wotton highlights British small caps that hit the sweet spot of the British equity market
By Ken Wotton Published
-
0DTE options: should you bet on America's favourite?
Zero-days-to-expiration (0DTE) options are popular with US traders seeking high leverage, but consistent profits by betting on short-term market direction are slim
By Theo Casey Published
-
Investing in defence: the easiest way to buy into the boom
The defence sector has taken off, but the opportunities for stock picking are more limited. We explain what to buy
By Frederic Guirinec Published
-
The investment opportunities in a bear market
As equities fell sharply in August, Max King explores the investment opportunities in a bear market
By Max King Published